Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence - Takeaways - MDSpire

Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence

  • By

  • Noa Antonissen

  • Steven Schalekamp

  • Horst K. Hahn

  • Kicky G. van Leeuwen

  • Colin Jacobs

  • May 7, 2026

  • 0 min

Share

  • 1

    Lung cancer is the leading cause of cancer-related mortality, and early detection via low-dose computed tomography (LDCT) significantly reduces mortality rates.

  • 2

    AI applications in lung cancer screening aim to alleviate radiologists' workload by automating interpretation and reporting of pulmonary nodules.

  • 3

    Numerous CE-marked AI products for lung nodule analysis are available, but their readiness for routine clinical use requires systematic evaluation.

  • 4

    The study evaluates AI products against established nodule management recommendations to identify capability gaps and support clinical adoption.

  • 5

    Task coverage scores were calculated to assess how well AI products support the tasks defined by various lung nodule management guidelines.

Original Source(s)

Commercial AI for CT lung cancer screening: product capabilities, coverage of nodule management tasks and supporting evidence

  • by Noa Antonissen, Steven Schalekamp, Horst K. Hahn, Kicky G. van Leeuwen, Colin Jacobs

  • May 7, 2026

Related Content

CT-based habitat imaging integrated with radiomics and clinicopathology for noninvasive prediction of microvascular invasion in hepatocellular carcinoma

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer